{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:21:06Z","timestamp":1761974466415,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.hpb.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T20:59:01Z","timestamp":1692737941000},"page":"1603-1605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Physician decision-making in the use of adjuvant chemotherapy for lymph node-positive gallbladder cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-4938","authenticated-orcid":false,"given":"McKenzie J.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schelomo","family":"Marmor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0251-4350","authenticated-orcid":false,"given":"David","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-8592","authenticated-orcid":false,"given":"Jacob","family":"Ankeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hpb.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hpb.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/hpb.12444","article-title":"Gallbladder Cancer: expert consensus statement","volume":"17","author":"Aloia","year":"2015","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijsu.2018.02.052","article-title":"Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial? (Results of a US-national retrospective cohort study)","volume":"52","author":"Bergquist","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.hpb.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"djw202","DOI":"10.1093\/jnci\/djw202","article-title":"Adjuvant therapy for resected gallbladder cancer: analysis of the national cancer data base","volume":"109","author":"Mantripragada","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hpb.2023.08.010_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw324","article-title":"Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival","volume":"109","author":"Mitin","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.hpb.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?: a Phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Tract","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J\u00a0R Soc Med"},{"issue":"suppl","key":"10.1016\/j.hpb.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"TPS620","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS620","article-title":"Optimal perioperative therapy for incidental gallbladder cancer (OPT-IN): a randomized phase II\/III trial\u2014ECOG-ACRIN EA2197","volume":"41","author":"Maithel","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X23019044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X23019044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:43:03Z","timestamp":1761266583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X23019044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1365182X23019044"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2023.08.010","relation":{},"ISSN":["1365-182X"],"issn-type":[{"type":"print","value":"1365-182X"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physician decision-making in the use of adjuvant chemotherapy for lymph node-positive gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}